Ignite Creation Date:
2024-05-06 @ 2:12 AM
Last Modification Date:
2024-10-26 @ 11:15 AM
Study NCT ID:
NCT01999985
Status:
COMPLETED
Last Update Posted:
2020-11-27
First Post:
2013-11-26
Brief Title:
Phase I Trial of Afatinib BIBW 2992 and Dasatinib in Non-small Cell Lung Cancer NSCLC
Sponsor:
H Lee Moffitt Cancer Center and Research Institute
Organization:
H Lee Moffitt Cancer Center and Research Institute
Study Overview
Official Title:
Phase I Trial Evaluating Safety and Tolerability of the Irreversible Epidermal Growth Factor Receptor Inhibitor Afatinib BIBW 2992 in Combination With the SRC Kinase Inhibitor Dasatinib for Patients With Non-small Cell Lung Cancer NSCLC
Status:
COMPLETED
Status Verified Date:
2020-11
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
The purpose of this study is to
Find out if the study drugs Afatinib and Dasatinib can be safely given together to patients with lung cancer
Learn how these two drugs work in cancer cells when they are combined
Learn more about the side effects of these two drugs when combined
Find the highest doses of the study drugs Afatinib and Dasatinib that can be given safely without causing serious side effects
Find out if the study drugs Afatinib and Dasatinib can be safely given together to patients with lung cancer
Learn how these two drugs work in cancer cells when they are combined
Learn more about the side effects of these two drugs when combined
Find the highest doses of the study drugs Afatinib and Dasatinib that can be given safely without causing serious side effects
Detailed Description:
None
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None
Secondary IDs
| Secondary ID | Type | Domain | Link |
|---|---|---|---|
| BMS CA180-379 | OTHER | Bristol-Myers Squibb | None |
| BI 1200166 | OTHER | None | None |